⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965093 | 0.75 | — | — | |
| SCHEMBL16612161 | 0.72 | — | — | |
| SCHEMBL519001 | 0.64 | — | — | |
| SCHEMBL16612256 | 0.64 | — | — | |
| SCHEMBL16612324 | 0.64 | — | — | |
| SCHEMBL16611915 | 0.62 | — | — | |
| SCHEMBL16612081 | 0.62 | — | — | |
| SCHEMBL519521 | 0.59 | — | — | |
| SCHEMBL16611766 | 0.59 | — | — | |
| SCHEMBL348521 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1157223-C | Dolastatin-15 derivatives in combination with taxanes | — | 2004-07-14 | — | — | CN | claimed |
| US-6632795-B1 | Treatment of cancer | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | claimed |
| EP-0981358-B1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AG (DE) | 2003-05-28 | — | — | EP | claimed |
| EP-1021200-B1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AG (DE) | 2002-02-06 | — | — | EP | claimed |
| CN-1278734-A | Methods and compositions for treating rheumatoid arthritis | BASF AG (DE) | 2001-01-03 | — | — | CN | claimed |
| US-6103698-A | USEFUL IN TREATING CANCER IN A MAMMAL; IN COMBINATION WITH PACLITAXEL AND TAXOTERE | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-15 | — | — | US | claimed |
| EP-1021200-A1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-26 | — | — | EP | claimed |
| CN-1252728-A | Combination of dolastatin-15 derivatives and taxanes | BASF AG (DE) | 2000-05-10 | — | — | CN | claimed |
| EP-0981358-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-01 | — | — | EP | claimed |
| US-6015790-A | Methods and compositions for treating rheumatoid arthritis | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-18 | — | — | US | claimed |
| WO-1999017792-A1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-15 | — | — | WO | claimed |
| WO-1999017709-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-15 | — | — | WO | claimed |
| US-5831002-A | HYBRID POLYPEPTIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-03 | — | — | US | claimed |
| WO-1998040092-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | claimed |
| CN-1157223-C | Dolastatin-15 derivatives in combination with taxanes | — | 2004-07-14 | — | — | CN | disclosed |
| US-6632795-B1 | Treatment of cancer | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| EP-0981358-B1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AG (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-1999017792-A1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-15 | — | — | WO | disclosed |
| US-5831002-A | HYBRID POLYPEPTIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-03 | — | — | US | disclosed |
| WO-1998040092-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |